Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 13/20 | 0.58 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277956 | 0.82 | ALDH1A1 (0.58) | NR1H2NR1H3MRGPRX4NPC1RAB9A | |
| SCHEMBL3279728 | 0.82 | NR1H2 (0.63) | NR1H2NR1H3NR1H4 | |
| SCHEMBL3280134 | 0.82 | NR1H2 (0.64) | NR1H2NR1H3NPC1CYP2D6CYP2C19 | |
| SCHEMBL1125878 | 0.75 | NR1H2 (0.78) | NR1H2NR1H3 | |
| SCHEMBL1171850 | 0.75 | MRGPRX4 (0.65) | MRGPRX4NR1H4 | |
| SCHEMBL3282748 | 0.75 | NR1H2 (0.61) | NR1H2NR1H3 | |
| SCHEMBL3279745 | 0.74 | NR1H2 (1.00) | NR1H2NR1H3 | |
| SCHEMBL1124992 | 0.73 | NR1H2 (0.78) | NR1H2NR1H3MRGPRX4 | |
| SCHEMBL3279332 | 0.73 | NR1H2 (0.60) | NR1H2NR1H3NR1H4 | |
| SCHEMBL8157075 | 0.72 | MRGPRX4 (0.70) | MRGPRX4NR1H4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700595-B2 | such as 3-benzyl-4-phenyl-8-(trifluoromethyl)cinnoline; modulators of Liver X receptors (LXRs) | WYETH LLC (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1853566-A1 | CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODULATORS | Wyeth (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060252757-A1 | Cinnoline compounds | WYETH | 2006-11-09 | — | — | US | disclosed |
| WO-2006094034-A1 | CINNOLINE COMPOUNDS AND THEIR USE AS LIVER X RECEPTOR MODILATORS | WYETH (US) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252757-A1 | Cinnoline compounds | NR1H3, NR1H2, CNR1 | NR1H2 2/4885NR1H3 1/4885MRGPRX4 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.